ArticleFrontiers in pharmacology2026
Machine-learning CT radiomics for prognostication in unresectable pancreatic cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable machine learning prediction of 1-year overall survival in pancreatic cancer patients aged 65 years and older.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to develop an interpretable radiomics-clinical model to predict overall survival (OS) in unresectable pancreatic cancer (PC). Methods: In this retrospective cohort, 202 patients with unresectable PC were enrolled. A total of 1,130 radiomics features were extracted from a region of interest encompassing the largest primary lesion using 3D-Slicer. Least absolute shrinkage and selection operator (LASSO)-selected features associated with OS were used to construct a radiomics risk score (RS). Independent clinical predictors were identified through stepwise Cox regression. A nomogram integrating RS with independent clinical predictors was built. Results: Median OS (mOS) for the entire cohort was 20.3 months. From 1,130 baseline CT radiomics features, LASSO retained 12 prognostic descriptors, which were linearly combined to compute a radiomics RS. Stepwise Cox regression identified age, sex, and CA19-9 as independent clinical predictors. A nomogram integrating RS with these variables was constructed in the training set. In the validation set, the area under the receiver operating characteristic curve (AUC) reached 0.804, 0.812, and 0.794 for 1-, 2-, and 3-year OS, respectively. Conclusion: An interpretable radiomics-clinical nomogram provided accurate survival prediction in unresectable pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.